Illumina Unveils TruSight™ Oncology 500 v2 for Comprehensive Genomic Profiling

Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

Home
/
update
/
details

Illumina Unveils TruSight™ Oncology 500 v2 for Comprehensive Genomic Profiling

NextEdge Admin

21 Nov 2024

2 min 20 sec

Illumina, a leader in DNA sequencing technologies, announced the upcoming launch of TruSight™ Oncology 500 v2 (TSO 500 v2), its latest cancer research assay for comprehensive genomic profiling (CGP). The assay, set for global release in mid-2025, will be showcased at the Association of Molecular Pathology (AMP) meeting on November 21 in Vancouver, British Columbia.

TSO 500 v2 enables analysis of hundreds of genes, variant classes, and immuno-oncology biomarkers from a single sample, enhancing therapy selection research. Key features include faster turnaround and reduced hands-on time, sensitive variant calling, and improved genomic region coverage. It incorporates the Myriad® Genomic Instability Score (GIS) to assess homologous recombination deficiency (HRD) and offers eco-friendly kits with reduced packaging. Advanced automation supports flexible batch sizes, with seamless integration of DRAGEN™ analysis and platforms like Illumina Connected Insights.

Preliminary analytical data and automation compatibility, to be presented at AMP, highlight its clinical research applications, including the identification of rare genetic and fusion biomarkers. Dr. Wei Song of UC San Diego, an early access user, praised the faster workflow, improved coverage, and lower DNA/RNA input requirements.

Illumina’s oncology portfolio supports both research-use and in-vitro diagnostic CGP solutions. Recent milestones include FDA approval of the TSO Comprehensive test and its companion diagnostic indications. At AMP, Illumina will cohost a workshop with Bayer on precision medicine challenges, underscoring CGP’s critical role in identifying actionable biomarkers for targeted therapies.